跳至主要内容
临床试验/NCT02672865
NCT02672865已完成1 期

Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer

Loma Linda University1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2016年2月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
4
试验地点
1
主要终点
Post Operative Complications

研究概览

简要总结

The purpose of this study is to determine safety and feasibility of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in patients with locally advanced gastric cancer undergoing standard surgical resection. Patients will be treated with HIPEC using a single dose of mitomycin 15mg/m2 and cisplatin 50mg/m2 at 41-42 C for 90 minutes, during the definitive surgical resection for gastric cancer. HIPEC will be performed after resection but before anastomosis.

详细描述

Treatment Plan:

Patients undergoing definitive resection for gastric cancer and meeting the eligibility criteria will be treated with HIPEC using a single dose of Mitomycin 15mg/m2 and Cisplatin 50mg/m2 at 41-42 C for 90 minutes. HIPEC will be performed after resection but before anastomosis. Both Cisplatin and Mitomycin are commercially available chemotherapeutic agents and will be obtained as marketed drugs.

Outcome Measures:

Patients will be followed for 90 days following surgery. All postoperative complications will be recorded and graded according to the modified Clavien-Dindo classification.

Schedule for Follow Up:

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18-75 with biopsy-proven gastric adenocarcinoma
  • Tumor clinically staged T3 or T4 and/or nodes staged clinically positive
  • ECOG performance status < 2

排除标准

  • Distant metastases
  • Peritoneal carcinomatosis
  • Synchronous malignancy
  • Tumors at the gastroesophageal junction
  • Recurrent gastric adenocarcinoma
  • Creatinine >/= 1.5
  • Bilirubin >/= 2
  • Allergy to drugs included in the treatment plan
  • Contraindication to major surgery

研究组 & 干预措施

HIPEC

Experimental

The administration of hyperthermic intraperitoneal chemotherapy (HIPEC), using a warm solution of two chemotherapy medications (mitomycin and cisplatin) to bathe the internal surfaces of the abdomen in an attempt to kill any microscopic cancer cells that might be present on these surfaces.

干预措施: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (Drug)

结局指标

主要结局

Post Operative Complications

时间窗: 90 days following surgery

Patients will be followed for 90 days following surgery. Postoperative complications will be recorded and graded according to the modified Clavien-Dindo classification.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Maheswari Senthil

MD

Loma Linda University

研究点 (1)

Loading locations...

相似试验

Adjuvant Hyperthermic Intraperitoneal Chemotherapy... | 临床试验